At-Home Use of a Pregnancy-Specific Zone-MPC Closed-Loop System for Pregnancies Complicated by Type 1 Diabetes: A Single-Arm, Observational Multicenter Study

Carol J. Levy, Yogish C. Kudva, Basak Ozaslan, Kristin Castorino, Grenye O’malley, Ravinder Jeet Kaur, Camilla M. Levister, Mei Mei Church, Donna Desjardins, Shelly McCrady-Spitzer, Selassie Ogyaadu, Mari Charisse Trinidad, Corey Reid, Shafaq Rizvi, Sunil Deshpande, Isabella Zaniletti, Walter K. Kremers, Jordan E. Pinsker, Francis J. Doyle, Eyal Dassau

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

OBJECTIVE There are no commercially available hybrid closed-loop insulin delivery systems customized to achieve pregnancy-specific glucose targets in the U.S. This study aimed to evaluate the feasibility and performance of at-home use of a zone model predictive controller–based closed-loop insulin delivery system customized for pregnancies complicated by type 1 diabetes (CLC-P). RESEARCH DESIGN AND METHODS Pregnant women with type 1 diabetes using insulin pumps were enrolled in the second or early third trimester. After study sensor wear collecting run-in data on personal pump therapy and 2 days of supervised training, participants used CLC-P targeting 80–110 mg/dL during the day and 80–100 mg/dL overnight running on an unlocked smartphone at home. Meals and activities were unrestricted through-out the trial. The primary outcome was the continuous glucose monitoring percentage of time in the target range 63–140 mg/dL versus run-in. RESULTS Ten participants (HbA1c 5.8 ± 0.6%) used the system from mean gestational age of 23.7 ± 3.5 weeks. Mean percentage time in range increased 14.1 percentage points, equivalent to 3.4 h per day, compared with run-in (run-in 64.5 ± 16.3% versus CLC-P 78.6 ± 9.2%; P = 0.002). During CLC-P use, there was significant decrease in both time over 140 mg/dL (P = 0.033) and the hypoglycemic ranges of less than 63 mg/dL and 54 mg/dL (P = 0.037 for both). Nine participants exceeded consensus goals of above 70% time in range during CLC-P use. CONCLUSIONS The results show that the extended use of CLC-P at home until delivery is feasible. Larger, randomized studies are needed to further evaluate system efficacy and pregnancy outcomes.

Original languageEnglish
Pages (from-to)1425-1431
Number of pages7
JournalDiabetes Care
Volume46
Issue number7
DOIs
StatePublished - Jul 2023

Fingerprint

Dive into the research topics of 'At-Home Use of a Pregnancy-Specific Zone-MPC Closed-Loop System for Pregnancies Complicated by Type 1 Diabetes: A Single-Arm, Observational Multicenter Study'. Together they form a unique fingerprint.

Cite this